Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Prep: Cook: Serves:

The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment.

INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people with Parkinson’s – is expected to be available in 2019.

Todd Sherer, CEO of The Michael J Fox Foundation, who funded early trials of the powder, said: “Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive.

“We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”

To read more on this topic click here.

For more information on Parkinson’s medication please visit the EPDA website.

Memory loss could be an indication of Parkinson’s

Last Month

Next Month

Go Back

Share this story

Comments

In my country

Tackling shame and loneliness in Italy

We speak to the founder of charity ParkinZone

World Parkinson Congress 2019 Bloggers: Allison Smith

#WPC2019: We talk to US blogger Allison Smith

Peace of mind: your Parkinson’s passport to a more comfortable holiday

‘Parkinson’s passport’ makes travelling easier

Can tremor predict the effect of Parkinson’s disease medication?

Researchers from the Netherlands have found a link between tremor symptoms and how dopaminergic medication impacts learning abilities in Parkinson’s disease. Many people with Parkinson’s become sensitive to learning through rewards due to a decrease in dopamine in the brain. As part of a new study – published in the scientific journal Brain –researchers assessed 43 tremor-dominant and 20 non-tremor dominant people with Parkinson’s while they were on and off dopaminergic medication. The results showed that in people with Parkinson’s who do not experience tremor, dopaminergic medication improves the ability to learn from rewards – and in those with tremor, the medication has no impact on reward learning. Rick Helmich, co-author of the study and a neurologist at Radboud University Medical Centre, the Netherlands, said: “Whether someone experiences tremor or not might therefore potentially have a significant predictive value regarding the effectiveness of medication in the cognitive domain. However, more…

Could a ‘Mediterranean diet’ lower the risk of Parkinson’s for women?

A study by scientists in Sweden has suggested that women who eat a ‘Mediterranean diet’ at middle age could have a lower risk of Parkinson’s later in life. The report, published in the Movement Disorders journal, used dietary information from more than 47,000 women aged 29 to 49, recorded between the early 1990s and 2012. They looked at how closely the women adhered to a Mediterranean dietary pattern (MDP), which is high in foods such as vegetables, fruits, nuts, unsaturated fats and legumes. They then compared the information with data from the Swedish National Patient Register to find out whether participants had been diagnosed with Parkinson’s. The researchers found that those with a high adherence to the diet had a 46% lower risk of being diagnosed with the condition compared to those with a low adherence, concluding that “higher adherence to a Mediterranean diet at middle age was associated with…

Pesticide that increases Parkinson’s risk by 150% reapproved in the US

The US Environmental Protection Agency (EPA) has allowed the continued use of paraquat, a pesticide that increases the risk of Parkinson’s disease by 150%. The pesticide – which has already been banned in 32 countries – was reapproved by the EPA in October as part of a review of the safety of all herbicides and pesticides in the US, a process which takes place every 15 years. Many studies have shown that as well as increased risk of Parkinson’s disease, exposure to the pesticide is associated with other health issues and risk of death. Exposure to paraquat endangers both the farmers who use the pesticide, as well as the families who can be exposed to it through the air or transfers onto clothing or other materials. In response to the reapproval, the Michael J Fox Foundation is calling on the Parkinson’s community to ask senators and representatives to support a…

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Email
This field is for validation purposes and should be left unchanged.

Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

In my country

Tackling shame and loneliness in Italy

Interviews

World Parkinson Congress 2019 Bloggers: Allison Smith

Resources & Tools

Peace of mind: your Parkinson’s passport to a more comfortable holiday

Can tremor predict the effect of Parkinson’s disease medication?

Could a ‘Mediterranean diet’ lower the risk of Parkinson’s for women?

Pesticide that increases Parkinson’s risk by 150% reapproved in the US

{title}

Subscribe

Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

In my country

Tackling shame and loneliness in Italy

Interviews

World Parkinson Congress 2019 Bloggers: Allison Smith

Resources & Tools

Peace of mind: your Parkinson’s passport to a more comfortable holiday

Can tremor predict the effect of Parkinson’s disease medication?

Could a ‘Mediterranean diet’ lower the risk of Parkinson’s for women?

Pesticide that increases Parkinson’s risk by 150% reapproved in the US

{title}

Subscribe

Sign in